# TEVIMBRA® (tislelizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tislelizumab

> The FDA approved TEVIMBRA® (tislelizumab), sponsored by BeOne Medicines Ltd. (ONC), on March 4, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is TEVIMBRA® (tislelizumab) FDA approved?

Yes. The FDA approved TEVIMBRA® (tislelizumab), sponsored by BeOne Medicines Ltd. (ONC), on March 4, 2025. SEC Form 10-Q: "On March 4, 2025, we announced the U.S. Food and Drug Administration has approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1)." [Calendar and source filings](https://sec-api.dev/pdufa/tislelizumab)

Source: SEC Form 10-Q, accession 0001651308-25-000075, https://www.sec.gov/Archives/edgar/data/1651308/000165130825000075/bgne-20250331.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/tislelizumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | TEVIMBRA® (tislelizumab) |
| Codes |  |
| Sponsor | BeOne Medicines Ltd. (ONC) https://sec-api.dev/companies/onc/catalysts |
| Indications | Advanced Esophageal Squamous Cell Carcinoma, [Non-small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Urothelial Carcinoma](https://sec-api.dev/indications/urothelial-carcinoma), Classical Hodgkin Lymphoma |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### Mar 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2026-05-06, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001628280-26-070477): "In March 2024, we subsequently received FDA approval for TEVIMBRA for this second-line indication." https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-030867): "In March 2024, we subsequently received FDA approval for TEVIMBRA for this second-line indication." https://www.sec.gov/Archives/edgar/data/1651308/000162828026030867/bgne-20260331.htm

### December 27, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0001651308-25-000031): "On December 27, 2024, we announced that the U.S. Food and Drug Administration ("FDA") approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (≥1)." https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/bgne-20241231.htm

### March 4, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-07, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001651308-25-000075): "On March 4, 2025, we announced the U.S. Food and Drug Administration has approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1)." https://www.sec.gov/Archives/edgar/data/1651308/000165130825000075/bgne-20250331.htm
- SEC Form 10-Q (accession 0001628280-26-070477): "In March 2025, we subsequently received FDA approval for TEVIMBRA for this first-line indication." https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-030867): "In March 2025, we subsequently received FDA approval for TEVIMBRA for this first-line indication." https://www.sec.gov/Archives/edgar/data/1651308/000162828026030867/bgne-20260331.htm

### May 30, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Non-small Cell Lung Cancer; NSCLC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04746924 (A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-05-12." https://clinicaltrials.gov/study/NCT04746924

### October 13, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Classical Hodgkin Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04486391 (Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor BeiGene." https://clinicaltrials.gov/study/NCT04486391

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-11-17, last confirmed 2025-11-17.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-283887): "We plan to quickly engage FDA and expect to submit a supplemental Biologics License Application (sBLA) in the U.S. in first half of 2026 to support Ziihera as a first-line treatment for patients with HER2+ locally advanced or metastatic GEA for use as part of a standard chemotherapy regimen with and without tislelizumab." https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm

### August 25, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-05, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001628280-26-070477): "On August 25, 2026, we announced that the U.S. Food and Drug Administration ("FDA") approved the supplemental Biologics License Application ("sBLA") for TEVIMBRA in combination with ZIIHERA and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2+ gastric, gastroesophageal junction, or GEA." https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Urothelial Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03967977 (Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor BeiGene." https://clinicaltrials.gov/study/NCT03967977

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Urothelial Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03967977 (Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor BeiGene." https://clinicaltrials.gov/study/NCT03967977

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07733180 (A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT07733180

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07733180 (A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT07733180

## Same indication

- [Calderasib](https://sec-api.dev/pdufa/calderasib) (MRK)
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [Disitamab vedotin](https://sec-api.dev/pdufa/disitamab-vedotin) (PFE)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [LBL-007](https://sec-api.dev/pdufa/lbl-007) (ONC)
- [Livmoniplimab](https://sec-api.dev/pdufa/livmoniplimab) (ABBV)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06), [February 2028](https://sec-api.dev/fda-calendar/2028-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tislelizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TEVIMBRA® (tislelizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tislelizumab

```bibtex
@misc{secapidev_pdufa_tislelizumab_20261116,
  title        = {TEVIMBRA® (tislelizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tislelizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tislelizumab_20261116","title":"TEVIMBRA® (tislelizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tislelizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
